Defective IL-10 expression and in vitro steroid-induced IL-17A in paediatric severe therapy-resistant asthma.
about
Vitamin D Actions on CD4(+) T Cells in Autoimmune DiseaseDifferentiating asthma phenotypes in young adults through polyclonal cytokine profiles.A Review on the Role of Vitamin D in Asthma.Mechanisms Mediating Pediatric Severe Asthma and Potential Novel Therapies.IL-17 in severe asthma. Where do we stand?1α,25-dihydroxyvitamin D3 acts via transforming growth factor-β to up-regulate expression of immunosuppressive CD73 on human CD4+ Foxp3- T cellsClinical characteristics of children and adolescents with severe therapy-resistant asthma in Brazil1,25D3 prevents CD8(+)Tc2 skewing and asthma development through VDR binding changes to the Cyp11a1 promoter.Vitamin D3 treatment of vitamin D-insufficient asthmatic patients does not alter immune cell function.Ketamine Inhalation Ameliorates Ovalbumin-Induced Murine Asthma by Suppressing the Epithelial-Mesenchymal Transition.Vitamin D influences asthmatic pathology through its action on diverse immunological pathways.Year in review 2014. Paediatric and adult clinical studies.The need to differentiate between adults and children when treating severe asthma.Vitamin D Counteracts an IL-23-Dependent IL-17A+IFN-γ+ Response Driven by Urban Particulate Matter.Immunopathology alters Th17 cell glucocorticoid sensitivity.ASTHMA - comparing the impact of vitamin D versus UVR on clinical and immune parameters.TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma.Severe therapy resistant asthma in children: translational approaches to uncover sub-phenotypes.Metabolic Disorders in Chronic Lung Diseases.Systemic Corticosteroid Responses in Children with Severe Asthma: Phenotypic and Endotypic Features.Vitamin D in pediatric age: consensus of the Italian Pediatric Society and the Italian Society of Preventive and Social Pediatrics, jointly with the Italian Federation of Pediatricians.Evaluation of Soluble CD48 Levels in Patients with Allergic and Nonallergic Asthma in Relation to Markers of Type 2 and Non-Type 2 Immunity: An Observational Study
P2860
Q28081150-026FE4F1-63E4-4131-90B7-620462BFBD1CQ33787281-89DCDD7E-719D-4742-9D72-8629DC06601AQ33853968-6F33657F-36C3-4B8B-9A8C-9FAF105E471CQ33871749-2280F297-1FF9-433F-99CF-90A69DEF7879Q34435370-98BD11A2-64B6-4A2D-81E8-8FB341F179AEQ36176421-E23AA55B-0E0F-444F-986F-4386529EB705Q36256597-10C44319-2917-4A4D-8718-513B72E65AC2Q36462037-025B11A8-F17D-45FD-A41A-2CDCB747DF86Q37062743-BCA53312-C2AE-4EC2-8E30-9E2C9D4286DFQ37120592-7CDBC89C-346A-4E18-8721-BBA017E6B7CBQ38294551-213E897E-E517-4211-AFFD-72ACB56EBC48Q38376166-79A26D5C-231A-4E69-8032-5AAFF4427991Q38547303-ACBEECAE-A0D2-4B39-9CDA-6DE1F4F3CB69Q38809435-721EB9AD-836A-4260-A1CA-F37FE94FF5EEQ38959155-4354759B-C027-4F3F-9127-A78C192F1F88Q39090564-19DF2326-37ED-4924-82E2-BF8CE9D1B8DAQ41042964-865421BA-FB80-40A8-9E7B-91850F7D6C59Q47796857-4BE20EAF-654A-4D93-A403-84BEC53E9C1DQ49795481-73B04CAF-0036-4125-AA26-36751462CBC2Q51450884-289637B6-1167-4ED8-90C0-5DF2285E1823Q55074474-BB89364E-143C-4AFF-A038-B23DEED160EFQ57300304-4E618DD0-0E1F-40A8-B14C-3A6A3F711EE8
P2860
Defective IL-10 expression and in vitro steroid-induced IL-17A in paediatric severe therapy-resistant asthma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Defective IL-10 expression and ...... vere therapy-resistant asthma.
@en
Defective IL-10 expression and ...... vere therapy-resistant asthma.
@nl
type
label
Defective IL-10 expression and ...... vere therapy-resistant asthma.
@en
Defective IL-10 expression and ...... vere therapy-resistant asthma.
@nl
prefLabel
Defective IL-10 expression and ...... vere therapy-resistant asthma.
@en
Defective IL-10 expression and ...... vere therapy-resistant asthma.
@nl
P2093
P50
P1433
P1476
Defective IL-10 expression and ...... vere therapy-resistant asthma.
@en
P2093
Andrew Bush
Atul Gupta
Cheryl Black
David F Richards
Kimuli Ryanna
P304
P356
10.1136/THORAXJNL-2013-203421
P407
P577
2013-12-17T00:00:00Z